SHR-A2009 With Bevacizumab Tested Against Sacituzumab Tirumotecan in Lung Cancer
Compares SHR-A2009 with bevacizumab to another drug in adults with advanced non-squamous lung cancer.
Plain-language title generated from the registry record
Registry title: SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-squamous non-small cell lung cancer that has spread locally or to other places. It compares SHR-A2009 plus bevacizumab with sacituzumab tirumotecan.
- Age
- 18 to 75 years, both ends included.
- Sex
- Men and women can join.
- Disease stage
- Locally advanced or metastatic non-squamous non-small cell lung cancer, confirmed by tissue or cell tests.
- Earlier treatment
- No chemotherapy, biological therapy, targeted therapy, immunotherapy or other trial drugs or treatments within 4 weeks before the first dose.
Main reasons for not taking part
- Untreated or active cancer spread to the brain or spinal cord (central nervous system)
- History of interstitial pneumonia, other moderate to severe lung disease, or earlier removal of a whole lung
- Severe bleeding tendency or clotting problem, or a blood clot in an artery or vein within 6 months
- Positive HIV test, or active hepatitis B or C
- Severe infection within 4 weeks before the first dose
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07895992, who can take part
Where in China
- Guangdong Provincial People's HospitalGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07895992
- Record updated
- 26 October 2026
- Original description
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancerRead full original descriptionShow less
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 in Combination With Bevacizumab Versus Sacituzumab Tirumotecan in Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined bevacizumab versus Sacituzumab Tirumotecan in the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer
Inclusion: voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; the age at the time of signing the informed consent form is 18-75 years old ( including both ends ), both men and women can; The ECOG score was 0 or 1; Participants with locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology; Adequate bone marrow and organ function.
Exclusion: Anti-tumor therapy such as chemotherapy, biological therapy, targeted therapy, immunotherapy or other unlisted clinical research drugs or treatments were received within 4 weeks before the first medication; History of interstitial pneumonia or participants who cannot rule out interstitial pneumonia ; or other moderate to severe lung diseases ; or received previous pneumonectomy surgery; Have a history of severe bleeding tendency or coagulation dysfunction ; bleeding symptoms with significant clinical significance occurred within 3 months before the first medication; Arterial and venous thrombosis events occurred within 6 months before the first administration ; Severe infection occurred within 4 weeks before the first administration; Imaging showed that the tumor invaded important organs or tumor surrounding / invasion of large blood vessels or there was obvious necrosis / cavity, which was judged by the researchers to have a risk of bleeding; Participants with severe cardiovascular and cerebrovascular diseases; HIV test positive; Participants with active hepatitis B or C; Allergy to any component of the treatment regimen; Untreated or active central nervous system tumor metastasis.